White paper: Recommendations on the conduct of superiority and organism-specific clinical trials of antibacterial agents for the treatment of infections caused by drug-resistant bacterial pathogens

Brad Spellberg, Eric P. Brass, John S. Bradley, Roger J. Lewis, David Shlaes, Paul G. Ambrose, Anita Das, Helen W. Boucher, Yohei Doi, John G. Bartlett, Robert A. Bonomo, Steven P. Larosa, George H. Talbot, Daniel Benjamin, Robert Guidos, Amanda Jezek, David N. Gilbert

研究成果: Article査読

67 被引用数 (Scopus)

抄録

There is a critical need for new pathways to develop antibacterial agents to treat life-threatening infections caused by highly resistant bacteria. Traditionally, antibacterial agents have been studied in noninferiority clinical trials that focus on one site of infection (eg, pneumonia, intra-abdominal infection). Conduct of superiority trials for infections caused by highly antibiotic-resistant bacteria represents a new, and as yet, untested paradigm for antibacterial drug development. We sought to define feasible trial designs of antibacterial agents that could enable conduct of superiority and organism-specific clinical trials. These recommendations are the results of several years of active dialogue among the white paper's drafters as well as external collaborators and regulatory officials. Our goal is to facilitate conduct of new types of antibacterial clinical trials to enable development and ultimately approval of critically needed new antibacterial agents.

本文言語English
ページ(範囲)1031-1046
ページ数16
ジャーナルClinical Infectious Diseases
55
8
DOI
出版ステータスPublished - 15-10-2012

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Infectious Diseases

フィンガープリント 「White paper: Recommendations on the conduct of superiority and organism-specific clinical trials of antibacterial agents for the treatment of infections caused by drug-resistant bacterial pathogens」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル